

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FLESCHER1

In re Application of:)	Conf. No.:
Eliezer FLESCHER et al.)	
)	
IA No: PCT/IL2004/001098)	Art Unit:
)	
IA Filed: December 1, 2004)	Examiner:
)	
Appln. No.:)	Washington, D.C.
Not yet assigned)	
)	June 2, 2006
For: JASMONATE DERIVATIVE)	
COMPOUNDS, PHARMACEUTICALS...)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[] B. before the mailing date of a first office action on the merits or before the mailing of a first Office

action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

[X] 3. Documents AF and AG are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of each document AF and AG (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[] For documents _____, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.

[X] A concise explanation of the relevance of document AF is found in the attached International Search Report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] A concise explanation of the relevance of document(s) _____ is set forth as follows:

[] A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.

[] A concise explanation of the relevance of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] 5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Sheridan Neimark
Registration No. 20,520

SN:lmh
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

G:\BN\W\Webb\Flescher1\Pto\2006-06-02ids.fee.doc

AP20 Rec'd PCT/PTO 02 JUN 2006

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	Not yet assigned 10/581546
Filing Date	Even date herewith
First Named Inventor	Eliezer FLESCHER
Group Art Unit	
Examiner Name	
Attorney Docket Number	FLESCHER1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US- 5,118,711 A	06-02-1992	Wilson et al.	
	AB	US- 5,436,226 A	07-25-1995	Lulai et al.	
	AC	US- 6,114,284 A	09-05-2000	Fujisawa et al.	
	AD	US- 6,469,061 B1	10-22-2002	Flescher et al.	
	AE	US- 2002/0173470 A1	11-21-2002	Flescher et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AF	JP 4-41414 A	02-12-1992	Fujisawa Pharmaceutical Co.		ABS
	AG	JP10-29935 A	02-03-1998	Noevir KK		ABS
	AH	WO 02/080890 A2	10-17-2002	Ramot University		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

1AP20 Rec'd PCT/PTO 02 JUN 2006

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet	2	3		Application Number	Not yet assigned 447581546
				Filing Date	Even date herewith
				First Named Inventor	Eliezer FLESCHER
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	FLESCHER1

NON PATENT LITERATURE DOCUMENTS /OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AI	Derwent publications Ltd., London, class B05, AN 1998-163664, xp002203872	
	AJ	Basaria et al, " Clinical review 138, anabolic-androgenic steroid therapy in treatment of chronic diseases", Journal of clinical endocrinology and metabolism, 86(11):5108-5117, November 2001	
	AK	Dangl et al., " Death don't have no mercy: cell death programs in plant-microbe interactions", The Plant Cell, Vol. 8, October 1996, p. 1793-1807	
	AL	Dermastia, Marina et al., "the effects of a plant growth regulator, jasmonic acid, on some mammalian fibroblast cell lines" Acta Pharm. (Zagreb) 1992, 42(4), 347-50 XP001085225	
	AM	Farmer et al., "Interplant communication: Airborne Methyl Jasmonate Induces Synthesis of Proteinase Inhibitors Plant Leaves", Proc. Natl. Acad. Sci. USA, vol. 87, oct.1990, p. 7713-7716	
	AN	Fingrut O. et al., " Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells", Bios. Infor. Service, Philadelphia, PA, US, XP000185234, 2002, 2002-04, Accession no. 200200324956 & Leukemia (Basingstoke), vol. 16, no. 4, April 2002 (2002-04), p. 608-616	
	AO	Gorospe et al., " Inhibition of G1 Cyclin-Dependent Kinase Activity...", Molecular and Cellular Biology, Mar. 1996, p. 762-770	
	AP	Ishii, Y. et al: " Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones", Leukemia, 18(18), 1413-1419, 2004 XP002328125	
	AQ	Kiyota, Hiromasa et al : " (.+.)-Methyl 11-fluorojasmonate as a designed antimetabolite of methyl jasmonate: synthesis and plant growth regulatory activity" XP002328126 & Nippon Noyaku Gakkaishi, 26(1), 96-99, 2001	
	AR	Lidija Klampfer et al., " Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines", Blood, vol. 93, no. 7 (April 1), 1999, p. 2386-2394	
	AS	Mittler et al., " Sacrifice in the face of foes: pathogen-induced programmed cell death in plants", Trends In Microbiology, Vol. 4, No. 1, January 1996, p. 10-15	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	Not yet assigned 217581546
			Filing Date	Enter date here with
			First Named Inventor	Eliezer FLESCHER
			Group Art Unit	
			Examiner Name	
			Attorney Docket Number	FLESCHER1
Sheet	3	3		

NON PATENT LITERATURE DOCUMENTS /OTHER INFORMATION			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AT	Nakaguchi, Osamu et al : " Hair growth stimulants containing dehydrodihydrojasmonic acid lower alkyl esters", XP002328128	
	AU	Okano et al., Chemical Abstracts, vol. 127, #200188v, 1997.	
	AV	Porter et al., "Emerging roles of caspass-3 in Apoptosis", Cell Death and differentiation, 1999, p. 99-104	
	AW	Ryals et at., " Systemic Acquired Resistance", The Plant Cell, vol. 8, Oct. 1996, p. 1809-1819	
	AX	Schierle K et al., " Homologues of Dihydro-12-oxo-phytodienoic acid and jasmonic acid by mixed kolbe electrolysis", Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 37, No. 48, 25 November 1996 (1996-11-25), P. 8715-8718, XP004068758	
	AY	Schwenger et al, " Cell-Type-Specific Activation Of C-Jun N-Terminal Kinase By Salicylates", J. Of Cellular Physiology, 179, 1999, p. 109-114	
	AZ	Schwenger et al., "Sodium salicylate induces apoptosis via p38 mitogen-activated...", Proc. Natl. Acad. Sci USA, 1997, p. 2869-2873	
	BA	Seiki et al., Chemical abstracts, vol. 126, #196471h, 1998	
	BB	Ward, Kerry et al : " The induction of proteinase inhibitor II by jasmonates" XP002328127, accession no. 1997 & Proceeding of the plant growth regulator society of America, 23 RD , 291-294, 1996	
	BC	Willingham, ""Cytochemical methods for the detection of apoptosis", The J. Of Histochemistry & Cytochemistry, vol. 47, p. 1101-1109, 1999	
	BD	Torii, Kousuke et al., " Evaluation of antiandrogen effect using SC-3 cells", Database accession no. 127:200188 XP002203871 & Nippon Koshohin Kagakkaishi (19970, 21(2), 97-102	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.